The changing face of acromegalyg - Advances in diagnosis and treatment

Nature Reviews Endocrinology

Volumn 8, Issue 10, 2012, Pages 605-611

  Ribeiro Oliveira Jr , Antônio ^a   Barkan, Ariel ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; GROWTH HORMONE RECEPTOR ANTAGONIST; HORMONE RECEPTOR BLOCKING AGENT; PASIREOTIDE; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; HUMAN GROWTH HORMONE;

ACROMEGALY; ARTERIAL WALL THICKNESS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COLON DIVERTICULOSIS; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; FOLLOW UP; GENERAL PRACTITIONER; GLUCOSE INTOLERANCE; GROWTH HORMONE RELEASE; HUMAN; HYPOPHYSIS TUMOR; NEURONAVIGATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; PATHOGENESIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REVIEW; THYROID CANCER; BLOOD; METABOLISM;

ACROMEGALY; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I;

EID: 84866626715     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2012.101     Document Type: Review

References (75)

1. Clemmons, D. R. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin. Chem. 57, 555-559 (2011).
2. Freda, P. U. et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 894-904 (2011).
3. Schneider, H. J. et al. A novel approach to the detection of acromegaly: accuracy of diagnosis by automatic face classification. J. Clin. Endocrinol. Metab. 96, 2074-2080 (2011).
4. Miller, R. E., Learned-Miller, E. G., Trainer, P., Paisley A. & Blanz, V. Early diagnosis of acromegaly: computers vs clinicians. Clin. Endocrinol. (Oxf). 75, 226-231 (2011).
5. Sabino, S. M., Miranda, P. A. & Ribeiro-Oliveira, A. Jr. Growth hormone-secreting pituitary adenomas: from molecular basis to treatment options in acromegaly. Cancer Biol. Ther. 9, 483-492 (2010).
6. Alexander, L., Appleton, D., Hall, R., Ross, W. M. & Wilkinson, R. Epidemiology of acromegaly in the Newcastle region. Clin. Endocrinol. (Oxf). 12, 71-79 (1980). (Pubitemid 10174985)
7. Fernandez, A., Karavitaki, N. & Wass, J. A. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. (Oxf). 72, 377-382 (2010).
8. Daly, A. F. et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 91, 4769-4775 (2006). (Pubitemid 44917305)
9. Rosario, P. W. & Calsolari, M. R. Screening for acromegaly by application of a simple questionnaire evaluating the enlargement of extremities in adult patients seen at primary health care units. Pituitary http://dx.doi.org/10.1007/s11102-011-0302-7.
10. Schneider, H. J., Sievers, C., Saller, B., Wittchen, H. U. & Stalla, G. K. High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin. Endocrinol. (Oxf). 69, 432-435 (2008).
11. Bjørndal, M. M., Sandmo Wilhelmsen, K., Lu, T. & Jorde, R. Prevalence and causes of undiagnosed hyperthyroidism in an adult healthy population. The Tromsø study. J. Endocrinol. Invest. 31, 856-860 (2008).
12. Rosario, P. W. Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population. Pituitary 14, 217-221 (2011).
13. Cannavò, S. et al. Increased prevalence of acromegaly in a highly polluted area. Eur. J. Endocrinol. 163, 509-513 (2010).
14. Dekkers, O. M., Biermasz, N. R., Pereira, A. M., Romijn, J. A. & Vandenbroucke, J. P. Mortality in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 93, 61-67 (2008).
15. Holdaway, I. M., Rajasoorya, R. C. & Gamble, G. D. Factors influencing mortality in acromegaly. J. Clin. Endocrinol. Metab. 89, 667-674 (2004). (Pubitemid 38269875)
16. Holdaway, I. M., Bolland, M. J. & Gamble, G. D. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol. 159, 89-95 (2008).
17. Sherlock, M. et al. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J. Clin. Endocrinol. Metab. 94, 4216-4223 (2009).
18. Reid, T. J. et al. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin. Endocrinol. (Oxf). 72, 203-208 (2010).
19. Stelmachowska-Banaś, M., Zdunowski, P. & Zgliczyński, W. Abnormalities in glucose homeostasis in acromegaly. Does the prevalence of glucose intolerance depend on the level of activity of the disease and the duration of the symptoms? Endokrynol. Pol. 60, 20-24 (2009).
20. Fieffe, S. et al. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur. J. Endocrinol. 164, 877-884 (2011).
21. Davi', M. V. et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur. J. Endocrinol. 159, 533-540 (2008).
22. Colao, A., Ferone, D., Marzullo, P. & Lombardi, G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 25, 102-152 (2004). (Pubitemid 38269977)
23. van der Klaauw, A. A. et al. Increased aortic root diameters in patients with acromegaly. Eur. J. Endocrinol. 159, 97-103 (2008).
24. Casini, A. F. et al. Aortic root ectasia in patients with acromegaly: experience at a single center. Clin. Endocrinol. (Oxf). 75, 495-500 (2011).
25. Paisley, A. N. et al. Changes in arterial stiffness but not carotid intimal thickness in acromegaly. J. Clin. Endocrinol. Metab. 96, 1486-1492 (2011).
26. Manara, R. et al. Increased rate of intracranial saccular aneurysms in acromegaly: an MR angiography study and review of the literature. J. Clin. Endocrinol. Metab. 96, 1292-1300 (2011).
27. Wassenaar, M. J. et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur. J. Endocrinol. 164, 475-483 (2011).
28. Wassenaar, M. J. et al. Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients. Growth Horm. IGF Res. 20, 226-233 (2010).
29. Wassenaar, M. J. et al. Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. Ann. Rheum. Dis. 70, 320-325 (2011).
30. Biermasz, N. R. et al. Automated image analysis of hand radiographs reveals widened joint spaces in patients with long term control of acromegaly: relation to disease activity and symptoms. Eur. J. Endocrinol. 166, 407-413 (2012).
31. Jayasena, C. N. et al. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin. Endocrinol. (Oxf). 75, 220-225 (2011).
32. Clayton, P. E., Banerjee, I., Murray, P. G. & Renehan, A. G. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat. Rev. Endocrinol. 7, 11-24 (2011).
33. Dworakowska, D. et al. Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. Eur. J. Endocrinol. 163, 21-28 (2010).
34. Gullu, B. E., Celik, O., Gazioglu, N. & Kadioglu, P. Thyroid cancer is the most common cancer associated with acromegaly. Pituitary 13, 242-248 (2010).
35. Wassenaar, M. J. et al. Acromegaly is associated with an increased prevalence of colonic diverticula: a case-control study. J. Clin. Endocrinol. Metab. 95, 2073-2079 (2010).
36. Annamalai, A. K. et al. Increased prevalence of gallbladder polyps in acromegaly. J. Clin. Endocrinol. Metab. 96, E1120-E1125 (2011).
37. Nachtigall, L. et al. Changing patterns in diagnosis and therapy of acromegaly over two decades. J. Clin. Endocrinol. Metab. 93, 2035-2041 (2008). (Pubitemid 351831512)
38. Wade, A. N. et al. Clinically silent somatotroph adenomas are common. Eur. J. Endocrinol. 165, 39-44 (2011).
39. Mercado, M. et al. Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly. J. Clin. Endocrinol. Metab. 93, 3411-3415 (2008).
40. Sakharova, A. A., Dimaraki, E. V., Chandler, W. F. & Barkan, A. L. Clinically silent somatotropinomas may be biochemically active. J. Clin. Endocrinol. Metab. 90, 2117-2121, (2005). (Pubitemid 40586248)
41. Ben-Shlomo, A. & Melmed, S. Acromegaly. Endocrinol. Metab. Clin. North Am. 37, 101-122 (2008).
42. Davidoff, L. M. Studies in acromegaly III. The anamnesis and symptomatology in one hundred cases. Endocrinology 10, 461-483 (1926).
43. Rivoal, O., Brézin, A. P., Feldman-Billard, S. & Luton, J. P. Goldmann perimetry in acromegaly: a survey of 307 cases from 1951 through 1996. Ophthalmology 107, 991-997 (2000).
44. Lonser, R. R., Kindzelski, B. A., Mehta, G. U., Jane, J. A. Jr & Oldfield, E. H. Acromegaly without imaging evidence of pituitary adenoma. J. Clin. Endocrinol. Metab. 95, 4192-4196 (2010).
45. Hartman, M. L. et al. Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. J. Clin. Endocrinol. Metab. 70, 1375-1384 (1990).
46. Bajuk Studen, K. & Barkan, A. Assessment of the magnitude of growth hormone hypersecretion in active acromegaly: reliability of different sampling models. J. Clin. Endocrinol. Metab. 93, 491-496 (2008). (Pubitemid 351240821)
47. Dimaraki, E. V., Jaffe, C. A., DeMott-Friberg, R., Chandler, W. F. & Barkan, A. L. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J. Clin. Endocrinol. Metab. 87, 3537-3542 (2002). (Pubitemid 34879493)
48. Giustina, A. et al. Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab. 85, 526-529 (2000). (Pubitemid 32273628)
49. Giustina, A. et al. A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95, 3141-3148 (2010).
50. Acromegaly Therapy Consensus Development Panel. Consensus statement: benefits versus risks of medical therapy for acromegaly. Am. J. Med. 97, 468-473 (1994).
51. Arafat, A. M. et al. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J. Clin. Endocrinol. Metab. 93, 1254-1262 (2008). (Pubitemid 351519718)
52. Jayasena, C. N., Wujanto, C., Donaldson, M., Todd, J. F. & Meeran, K. Measurement of basal growth hormone (GH) is a useful test of disease activity in treated acromegalic patients. Clin. Endocrinol. (Oxf). 68, 36-41 (2008). (Pubitemid 350243479)
53. Carmichael, J. D., Bonert, V. S., Mirocha, J. M. & Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J. Clin. Endocrinol. Metab. 94, 523-527 (2009).
54. Ribeiro-Oliveira, A. Jr, Faje, A. T. & Barkan, A. L. Limited utility of oral glucose tolerance test in biochemically active acromegaly. Eur. J. Endocrinol. 164, 17-22 (2011).
55. Kraftson, A. & Barkan, A. Quantification of day-to-day variability in growth hormone levels in acromegaly. Pituitary 13, 351-354 (2010).
56. Pokrajac, A. et al. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin. Endocrinol. (Oxf). 67, 65-70 (2007). (Pubitemid 46955441)
57. Bidlingmaier, M. & Freda, P. U. Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences. Growth Horm. IGF Res. 20, 19-25 (2010).
58. Stonesifer, L. D., Jordan, R. M. & Kohler, P. O. Somatomedin C in treated acromegaly: poor correlation with growth hormone and clinical response. J. Clin. Endocrinol. Metab. 53, 931-934 (1981). (Pubitemid 13229570)
59. Clemmons, D. R. et al. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N. Engl. J. Med. 301, 1138-1142 (1979). (Pubitemid 10158784)
60. Barkan, A. L., Beitins, I. Z., Kelch, R. P. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J. Clin. Endocrinol. Metab. 67, 69-73 (1988).
61. Faje, A. T. & Barkan, A. L. Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-I. J. Clin. Endocrinol. Metab. 95, 2486-2491 (2010).
62. Sherlock, M. et al. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly. Clin. Endocrinol. (Oxf). 71, 74-81 (2009).
63. Ribeiro-Oliveira, A. Jr, Faje, A. & Barkan, A. Postglucose growth hormone nadir and insulin-like growth factor-1 in naive-active acromegalic patients. Arq. Bras. Endocrinol. Metab. 55, 494-497 (2011).
64. Chen, J. W. et al. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am. J. Physiol. Endocrinol. Metab. 284, E1149-E1155 (2003).
65. Brugts, M. P. et al. Normal values of circulating insulin-like growth factor-I bioactivity on the healthy population: comparison with five widely used IGF-I immunoassays. J. Clin. Endocrinol. Metab. 93, 2539-2545 (2008). (Pubitemid 352008517)
66. Bianchi, A. et al. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J. Clin. Endocrinol. Metab. 94, 2015-2022 (2009).
67. Dos Santos, C. et al. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat. Genet. 36, 720-724 (2004). (Pubitemid 38886633)
68. Leontiou, C. A. et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J. Clin. Endocrinol. Metab. 93, 2390-2401 (2008). (Pubitemid 351831563)
69. Laws, E. R. Surgery for acromegaly: evolution of the techniques and outcomes. Rev. Endocr. Metab. Disord. 9, 67-70 (2008).
70. Ben-Shlomo, A. & Melmed, S. Somatostatin agonists for treatment of acromegaly. Mol. Cell. Endocrinol. 286, 192-198 (2008).
71. Kopchick, J. J. Discovery and development of a new class of drugs: GH antagonists. J. Endocrinol. Invest. 26, 16-26 (2003).
72. Sherlock, M., Woods, C. & Sheppard, M. C. Medical therapy in acromegaly. Nat. Rev. Endocrinol. 7, 291-300 (2011).
73. Petersenn, S. et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J. Clin. Endocrinol. Metab. 95, 2781-2789 (2010).
74. Birzniece, V., Sata, A. & Ho, K. K. Growth hormone receptor modulators. Rev. Endocr. Metab. Disord. 10, 145-156 (2009).
75. Somm, A. E. et al. SXN101742, a botulinum toxin-derived targeted secretion inhibitor (TSI) inhibits GH synthesis and secretion: a new concept for the management of acromegaly [abstract]. Endocr. Rev. 32, Abstract P1-P413 (2011).